-
Volatility Continues in Affymax; Stock Jumps 22%
Wednesday, March 20, 2013 - 4:13pm | 642Read More...Over the last month, shares of biotech firm Affymax (NASDAQ: AFFY) have lost around 92 percent of their value. The company currently has a market cap of under $50 million. The catalyst for the plunge in the stock price was the recall of the company's only marketed product -- an anemia treatment...
-
Horizon Pharma Tops EPS Estimates, Falls Short on Revenue
Monday, March 18, 2013 - 11:54am | 428Read More...Horizon Pharma (NASDAQ: HZNP) is down on Monday despite topping estimates during the fourth quarter and full year. The Deerfield, Illinois firm posted a loss of $0.34 per share, topping its Q4 2011 performance of a $0.97 loss. This figure also easily topped the Wall Street consensus of a $0.47...
-
Affymax Drops to All-Time Low After Recall
Monday, February 25, 2013 - 1:03pm | 391Read More...It's been a rough few months for Affymax (NASDAQ: AFFY). After a steady climb to nearly $25 in late November, the Palo Alto, California biotech firm has been on a backslide. The stock fell into the mid-teens by mid-February and hovered there through Friday. Then, on Saturday, Affymax and Takeda...
-
UPDATE: Piper Jaffray Raises Amgen PT to $107, Says Short Term Strength Expected From Omontys Failure
Monday, February 25, 2013 - 12:01pm | 186Read More...In a report published Sunday, Piper Jaffray reiterated an Overweight rating for Amgen (NASDAQ: AMGN) and raised its price target from $104 to $107. In the report, Piper Jaffray wrote, "We remain Overweight and are increasing our price target to $107 from $104 following the safety recall of Affymax'...
